Zonisamide for bipolar disorder, mania or mixed states: A randomized, double blind, placebo-controlled adjunctive trial

Psychopharmacology Bulletin

Volumn 44, Issue 1, 2011, Pages 5-17

  Dauphinais, Deborah ^a   Knable, Michael ^a   Rosenthal, Joshua ^a   Polanski, Mark ^a   Rosenthal, Norman ^a  

^a Bethesda Behavioral Sciences   (United States)

Author keywords

Adjuvant treatment; Bipolar disorder; Mood disorder; Mood stabilize; Treatment efficacy

Indexed keywords

GLUCOSE; MICROCRYSTALLINE CELLULOSE; MOOD STABILIZER; TRIACYLGLYCEROL; ZONISAMIDE;

ADJUVANT THERAPY; ADULT; ANXIETY; ARTICLE; BEDTIME DOSAGE; BIPOLAR DISORDER; BIPOLAR I DISORDER; BIPOLAR II DISORDER; BIPOLAR MANIA; BODY MASS; CLINICAL GLOBAL IMPRESSION SCALE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPOMANIA; MAJOR CLINICAL STUDY; MALE; MANIA; MONTGOMERY ASBERG DEPRESSION RATING SCALE; MORNING DOSAGE; MULTICENTER STUDY; NAUSEA; OUTCOME ASSESSMENT; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SUICIDE ATTEMPT; TRIACYLGLYCEROL BLOOD LEVEL; WAIST HIP RATIO; WEIGHT; XEROSTOMIA; YOUNG MANIA RATING SCALE;

ADULT; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; CYCLOTHYMIC DISORDER; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; ISOXAZOLES; MALE; MIDDLE AGED; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 82155183135     PISSN: 00485764     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Kessler RC, McGonagle KA, Zhao S, Nelson CB, Hughes M, Eshleman S, Wittchen HU, Kendler KS. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Arch Gen Psychiatry. 1994;51:8-19.
2. Angst J. The emerging epidemiology of hypomania and bipolar II disorder. J Affect Disorders. 1998;50:143-151.
3. Perlis RH, Ostacher MJ, Patel JK, Marangell LB, Zhang H, Wisniewski SR, Ketter TA, Miklowitz DJ, Otto MW, Gyulai L, Reilly-Harrington NA, Nierenberg AA, Sachs GS, Thase ME. Predictors of recurrence in bipolar disorder: Primary outcomes from the systematic treatment enhancement program for bipolar disorder (STEP-BD). Am J Psychiatry. 2006;163: 217-224.
4. Kanba S, Yagi G, Kamijima K, Suzuki T, Tajima O, Otaki J, Arata E, Koshikawa H, Nibuya M, Kinoshita N, et al. The first open study of zonisamide, a novel anticonvulsant, shows efficacy in mania. Prog Neuropsychopharmacol Biol Psychiatry. 1994;18(4):707-715.
5. Ghaemi SN, Shirzadi AA, Klugman J, Berv DA, Pardo TB, Filkowski MM. Is adjunctive open-label zonisamide effective for bipolar disorder? Journal of Affective Disorders. 2008;105:311-314.
6. McElroy SL, Suppes T, Keck PE, Black D, Frye MA, Altshuler LL, Nolen WA, Kupka RW, Leverich GS, Walden J, Grunze H, Post RM. Open-label adjunctive zonisamide in the treatment of bipolar disorders: a prospective trial. J Clin Psychiatry. 2005;66(5):617-624.
7. Anand A, Bukhari L, Jennings SA, Lee C, Kamat M, Shekhar A, Nurnberger JI, Lightfoot J. A preliminary open-label study of zonisamide treatment for bipolar depression in 10 patients. J Clin Psychiatry. 2005;66:195-198.
8. Baldassano CF, Ghaemi NS, Chang A, Lyman A, Lipari M. Acute treatment of bipolar depression with adjunctive zonisamide: a retrospective chart review. Bipolar Disord. 2004;6(5):432-434.
9. Ghaemi SN, Zablotsky B, Filkowski MM, Dunn RT, Pardo TB, Isenstein E, Baldassano CF. An open prospective study of zonisamide in acute bipolar depression. J Clin Psychopharmacol. 2006;26(4): 385-388.
10. Oommen KJ and Mathews S. Zonisamide: a new antiepileptic drug. Clin Neuropharmacol. 1999;22(4):192-200.
11. Ghaemi SN and Gaughan S. Novel anticonvulsants: a new generation of mood stabilizers? Harv Rev Psychiatry. 2000;8(1):1-7.
12. Elmslie JL, Silverstone JT, Mann JI,Williams SW, Romans SE. Prevalence of overweight and obesity in bipolar patients. J Clin Psychiatry. 2000;61:179-84.
13. Fagiolini A, Kupfer DJ, Houck PR, Novick DM, Frank E. Obesity as a correlate of outcome in patients with bipolar I disorder. Am J Psychiatry. 2003;160(1):112-117.
14. Keck PE and McElroy SL. Bipolar disorder, obesity, and pharmacotherapy-associated weight gain. J Clin Psychiatry. 2003;64(12):1426-1435.
15. McElroy SL, Frye MA, Suppes T, Dhavale D, Keck PE, Leverich GS, Altshuler L, Denicoff KD, Nolen WA, Kupka R, Grunze H, Walden J, Post RM. Correlates of overweight and obesity in 644 patients with bipolar disorder. J Clin Psychiatry. 2002;63:207-213.
16. Sills GJ and Brodie MJ. Pharmacokinetics and drug interactions with zonisamide. Epilepsia. 2007:48(3);435-441.
17. Diagnostic and Statistical Manual of Mental Disorders. 4th ed.Washington, DC: American Psychiatric Association Washington, APA Press;1994.
18. Sheehan D, Janava J, Baker R, Harnett-Sheehan K, Knapp E, Sheehan M. Mini International Neuropsychiatric Interview. 2006:Version 5.0.0. Sheehan, D.V. and Lecrubier, Y., University of South Florida, Tampa and Hôpital de la Salpétrière, Paris:Copyright 1992-2006.
19. Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania: reliability, validity, and sensitivity. Br J Psychiatry. 1978;133:429-435.
20. Montgomery SA and Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134:382-389.
21. Williams JBW, Kobak KA. Development and reliability of a structured interview guide for the Montgomery-Asberg Depression Rating Scale (SIGMA). Br J Psychiatry. 2008;192:52-58.
22. Spearing MK, Post RM, Leverich GS, Brandt D, Nolen W. Modification of the Clinical Global Impressions (CGI) scale for use in bipolar illness (BP): the CGI-BP. Psychiatry Res. 1997; 73(3):159-171.
23. Endicott J, Nee J, Harrison W, Blumenthal R.Quality of life enjoyment and satisfaction questionnaire: a new measure. Psychopharmacol Bull. 1993;29(2):321-326.
24. Bray GA, Gray DS. Obesity. Part I-Pathogenesis. West J Med. 1988;149:429-441.
25. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: the evidence report. National Heart, Lung, and Blood Institute in cooperation with The National Institute of Diabetes and Digestive and Kidney Diseases. 1998: NIH Publication No. 98-4083. Rockville, MD: National Institutes of Health.
26. Systematic Assessment for Treatment Emergent Effects (SAFTEE). 1986: Rockville, MD: National Institute of Mental Health.
27. Moher D, Schulz KF, Altman DG. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. Lancet. 2001;357(9263):1191-1194.
28. Schulz KF, Altman DG, Moher D, for the CONSORT Group. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomized trials. Ann Int Med. 2010;152. Epub 24 March.
29. McElroy SL, Kotwal R, Guerdjikova AI, Welge JA, Nelson EB, Lake KA, D'Alessio DA, Keck, PE, Hudson JI. Zonisamide in the treatment of binge eating disorder with obesity: a randomized controlled trial. J Clin Psychiatry. 2006;67:1897-1906.
30. Gadde KM, Franciscy DM, Wagner HR 2nd, Krishnan KRR. Zonisamide for weight loss in obese adults: A randomized controlled trial. JAMA. 2003;289(4):1820-1825.
31. Orexigen Therapeutics, Inc., Orexigen Press Release. Available at http://ir.orexigen.com/phoenix.zhtml?c=207034&p=irol-newsArticle. Accessed October 25, 2009 and October 12, 2010.
32. Endocrinology.Trials: Empatic 360. Center Watch Weekly. Boston, MA. Center Watch; 2009;13(40):14.
33. Arias AJ, Feinn R, Oncken C, Covault J, Kranzler HR. Placebo-controlled trial of zonisamide for the treatment of alcohol dependence. J Clin Psychopharmacology. 2010;30(3):318-322.